It is widely recognized that the current process of membrane protein antibody discovery faces three major challenges:

1. Insufficient availability of highly immunogenic antigens

2. Lack of antigens that enhance antibody specificity

3. Absence of efficient screening methods for membrane protein antibodies

Additionally, GPCRs pose unique difficulties due to the highly variable conformations of their extracellular regions, the limited exposure of extracellular epitopes, and the complexities associated with antigen preparation. These factors have rendered the development of therapeutic antibodies a persistent challenge in the industry.

Our MegAb antibody development platform effectively addresses these critical issues.

MegAb Membrane Protein Antibody Discovery Platform

1. We developed UltraVLP (virus-like particles) to address the issue of low immunogenicity of antigens. What makes these UltraVLP unique is that they incorporate immune-enhancing components, significantly boosting the immune response to membrane proteins.

2. We developed AquaVLP (virus-like particles) to improve the specificity of antibodies. The uniqueness of these AquaVLP lies in the fact that we have reconstructed purified membrane proteins within them, achieving over 90% representation of the target protein compared to traditional VLPs. This innovative approach significantly enhances the specific immune response to the target protein.

3. Unlike other companies that can only use cell membrane fragments or cells for antibody screening during the development of antibodies against membrane proteins (especially GPCRs), Alphelix can easily and quickly use purified membrane proteins for antibody screening. Ultimately, we have greatly improved the efficiency of therapeutic antibody development for membrane proteins through traditional hybridoma technology or microdroplet/microfluidic high-throughput sorting technology.

Services and Duration